SG11201906392WA - Nucleoside-modified rna for inducing an immune response against zika virus - Google Patents

Nucleoside-modified rna for inducing an immune response against zika virus

Info

Publication number
SG11201906392WA
SG11201906392WA SG11201906392WA SG11201906392WA SG11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA SG 11201906392W A SG11201906392W A SG 11201906392WA
Authority
SG
Singapore
Prior art keywords
zikv
international
nucleoside
mrna
immune response
Prior art date
Application number
SG11201906392WA
Inventor
Drew Weissman
Norbert Pardi
Michael Hogan
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of SG11201906392WA publication Critical patent/SG11201906392WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CM . I \" c e lls ( %) .6 0,4 0.2 0.0 IL-2 4 • • • • • * • 0.8 o.e 0.4 0.2 0,0 Control ZIKV mRNA N 00 O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WIPO I PCT ill~~~~~~~~ 0mi110VIIIOH olo m1°111°11111 No oimIE (10) International Publication Number WO 2018/132537 Al (51) International Patent Classification: A61K 39/12 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/013270 (22) International Filing Date: 11 January 2018 (11.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/444,931 11 January 2017 (11.01.2017) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors: WEISSMAN, Drew; 218 Lloyd Lane, Wyn- newood, PA 19096 (US). PARDI, Norbert; 873 N. 23rd Street, Philadelphia, PA 19130 (US). HOGAN, Michael; 2205 Fitzwater Street, Apt. 2, Philadelphia, PA 19146 (US). (74) Agent: SINGH, Pallab et al.; Riverside Law, LLP, Glen- hardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN IMMUNE RESPONSE AGAINST ZIKA VIRUS Contml • ZIKV prM-E mRNA-LNP IFNy , 18 • • e• Control ZIKV mRNA. Go ZIKV mRNA (57) : The present invention relates to compositions and methods for inducing adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside- modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. Figure 1A 0 15 0.4 13 0.2 0.1 0.0 • • • e• • C57BL/6 iNr`
SG11201906392WA 2017-01-11 2018-01-11 Nucleoside-modified rna for inducing an immune response against zika virus SG11201906392WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444931P 2017-01-11 2017-01-11
PCT/US2018/013270 WO2018132537A1 (en) 2017-01-11 2018-01-11 Nucleoside-modified rna for inducing an immune response against zika virus

Publications (1)

Publication Number Publication Date
SG11201906392WA true SG11201906392WA (en) 2019-08-27

Family

ID=62839708

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906392WA SG11201906392WA (en) 2017-01-11 2018-01-11 Nucleoside-modified rna for inducing an immune response against zika virus

Country Status (10)

Country Link
US (2) US11241490B2 (en)
EP (1) EP3568155A4 (en)
JP (2) JP7317715B2 (en)
CN (1) CN110381994B (en)
AU (1) AU2018207408A1 (en)
BR (1) BR112019014314A2 (en)
CA (1) CA3049991A1 (en)
MX (1) MX2019008303A (en)
SG (1) SG11201906392WA (en)
WO (1) WO2018132537A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
MA42502A (en) 2015-07-21 2018-05-30 Modernatx Inc VACCINES AGAINST INFECTIOUS DISEASE
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. Tropical disease vaccines
EP3416683A1 (en) 2016-02-17 2018-12-26 CureVac AG Zika virus vaccine
CN115927399A (en) * 2016-02-25 2023-04-07 宾夕法尼亚大学理事会 Novel vaccine against Zika virus
EP3532097A1 (en) * 2016-10-27 2019-09-04 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
WO2019036030A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019055807A1 (en) * 2017-09-14 2019-03-21 Modernatx, Inc. Zika virus rna vaccines
EP3723796A1 (en) 2017-12-13 2020-10-21 CureVac AG Flavivirus vaccine
WO2021197589A1 (en) * 2020-03-31 2021-10-07 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination
KR20230051172A (en) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. Cationic Lipids for Use in Lipid Nanoparticles
CN115197079A (en) * 2021-04-08 2022-10-18 厦门赛诺邦格生物科技股份有限公司 Polyethylene glycol lipid and liposome modified by same, pharmaceutical composition containing liposome, preparation and application of pharmaceutical composition
WO2023051926A1 (en) * 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2024055000A1 (en) * 2022-09-09 2024-03-14 The Trustees Of The University Of Pennsylvania Compositions and methods comprising lipid nanoparticle vaccines that elicit a modulated immune response

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856420A (en) 1955-12-15 1958-10-14 Minnesota Mining & Mfg Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols
US3340299A (en) 1964-03-27 1967-09-05 Air Reduction Tetrasubstituted ethylene diamines
IT949755B (en) 1972-03-01 1973-06-11 Snam Progetti PROCEDURE FOR THE PRODUCTION OF ALUMINUM CHLOROHYDROXIDES WITH CONTROLLED CHLORINE
JPS5122416B2 (en) 1972-11-11 1976-07-09
JP4111856B2 (en) 2002-04-12 2008-07-02 昭和電工株式会社 Stabilized ascorbic acid derivatives
CA2611944A1 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
ES2735531T3 (en) 2005-08-23 2019-12-19 Univ Pennsylvania RNA containing modified nucleosides and methods of use thereof
US20090082803A1 (en) 2007-09-26 2009-03-26 Aga Medical Corporation Braided vascular devices having no end clamps
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
CA2816925C (en) 2009-11-04 2023-01-10 The University Of British Columbia Nucleic acid-containing lipid particles and related methods
KR101773643B1 (en) 2010-04-28 2017-08-31 교와 핫꼬 기린 가부시키가이샤 Cationic lipid
WO2011143230A1 (en) 2010-05-10 2011-11-17 Alnylam Pharmaceuticals Methods and compositions for delivery of active agents
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
JP2014508102A (en) 2010-11-15 2014-04-03 ライフ テクノロジーズ コーポレーション Amine-containing transfection reagents and methods for producing and using the same
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP2013095755A (en) 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd Cationic lipid
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US20160030527A1 (en) 2013-03-14 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and Methods for Treatment of Stroke
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
JP6881813B2 (en) 2014-04-23 2021-06-02 モデルナティーエックス， インコーポレイテッド Nucleic acid vaccine
CN106537012B (en) 2014-05-22 2019-02-12 福斯有限责任公司 For valve actuator induction element and be provided with the actuator of the induction element
SI3766916T1 (en) 2014-06-25 2023-01-31 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016145149A1 (en) * 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
CA2984125A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
US10799575B2 (en) * 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
US10221127B2 (en) 2015-06-29 2019-03-05 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
MA42502A (en) 2015-07-21 2018-05-30 Modernatx Inc VACCINES AGAINST INFECTIOUS DISEASE
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. Tropical disease vaccines
FI3368507T3 (en) 2015-10-28 2023-03-21 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Also Published As

Publication number Publication date
BR112019014314A2 (en) 2020-02-18
AU2018207408A1 (en) 2019-08-08
US20220184201A1 (en) 2022-06-16
EP3568155A1 (en) 2019-11-20
EP3568155A4 (en) 2020-09-23
CA3049991A1 (en) 2018-07-19
CN110381994B (en) 2024-05-10
MX2019008303A (en) 2019-12-02
JP2020505444A (en) 2020-02-20
WO2018132537A1 (en) 2018-07-19
US11241490B2 (en) 2022-02-08
US20190358314A1 (en) 2019-11-28
JP7317715B2 (en) 2023-07-31
CN110381994A (en) 2019-10-25
JP2023134745A (en) 2023-09-27

Similar Documents

Publication Publication Date Title
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus
SG11201811432WA (en) Rna for cancer therapy
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201907714UA (en) Adeno-associated virus (aav) clade f vector and uses therefor
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201903514VA (en) Novel cd47 monoclonal antibodies and uses thereof
SG11201909949XA (en) Targeted immunotolerance
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201810777WA (en) Purification of multispecific antibodies
SG11201901206SA (en) Trimer stabilizing hiv envelope protein mutations
SG11201806340YA (en) Zika virus vaccine
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201803701YA (en) Methods and compositions for gene editing in hematopoietic stem cells
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805645QA (en) Lsd1 inhibitors
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808422QA (en) Gene therapy for treating hemophilia a
SG11201408153YA (en) Prostate-specific membrane antigen antibody drug conjugates
SG11201810525XA (en) Anti-gitr antibodies and uses thereof